摘要
目的:评价吉西他滨联合顺铂治疗非小细胞肺癌的疗效及毒副作用。方法:30例晚期非小细胞肺癌,初治14例,复治16例,采用吉西他滨1000mg/m2,第1、8天静脉滴注。顺铂:80mg/m2,分3天静脉滴注,21天为1个周期,至少连用2个周期。结果:部分缓解(PR)14例,无变化(NC)13例,病变进展(PD)3例,有效率为46.67%。主要毒副反应为骨髓抑止、恶心和呕吐等。结论:吉西他滨联合顺铂对治疗非小细胞肺癌有较好的临床疗效,毒副反应轻,易耐受。
Purpose：To observe the efficacy and toxicity of gemcitabine plus cisplatin in the treatment of advanced non-small-cell lung cancer（NSCLC）.Methods：Among 30 NSCLC eascs.14 patients were untreated tumor eases,16 were recurrent tumor cases.They were all treated by gemcitabine plus cisplatin,Results：The response rate（CR＋PR）was 45.67%,NC13 PD3.The major toxicity inchuded meutropenia,nausea and vomiting.Conclusions：The regimen of gemcitabine in combination with cisplatin is effective,safe and well-tolenated in the treatment of NSCLC.
出处
《中国癌症杂志》
CAS
CSCD
2005年第4期385-386,共2页
China Oncology
关键词
非小细胞肺癌
化疗
吉西他滨
顺铂
mon-small-cell lung cancer
drug thenapy
gentcitabine
eisplatin
